Marksans Pharma Ltd (NSE:MARKSANS)

Q2 2026 Marksans Pharma Ltd Earnings Call Transcript

Nov 14, 2025 / 11:30 AM GMT

Release Date Price: ₹192.44 (+2.17%)

Transcript

Key Points

Positve

Marksans Pharma Ltd (BOM:524404) reported a 16% sequential revenue growth in Q2 FY26, driven by improved demand and operational execution.
The US market showed robust performance with a 27% year-on-year revenue increase, supported by new product launches in digestive health and pain management.
The UK business remained stable despite pricing pressures, with three new marketing authorizations from UK MHRA, strengthening the product portfolio.
EBITDA and PAT grew by 44% and 70% quarter-on-quarter, respectively, due to operating leverage and improved cost efficiencies.
The company successfully completed a US FDA inspection at its Verna Goa facility with zero Form 483 observations, reaffirming strong compliance standards.

Negative

Price erosion for RX products remains a concern, although currently in low single digits.
The UK market continues to face significant pricing pressures, impacting gross margins.
The company's gross margin decreased to 57.2% from 59.7% last year, primarily due to product mix and pricing pressure in the UK.
EBITDA margin decreased by 108 basis points year-on-year, despite sequential improvement.
Working capital cycle remains high at 150 days, although improvements are expected in the coming quarters.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MARK.NS - Marksans Pharma Ltd
Q2 2026 Marksans Pharma Ltd Earnings Call
Nov 14, 2025 / 11:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to the Markins Pharma Q2 FY26 earning conference call hosted by Dam Capital Advisors Limited. As a reminder, all the participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing, then 0 on your touchstone phone. Please note that this conference has been recorded. I now hand the conference over to Mr. Nitin Agarwal.

Thank you and over to you, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]
---------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.